Resverlogix

Resverlogix Corp. operates as a late-stage clinical biotechnology firm with a focus on epigenetic therapies for chronic illnesses. Founded in 2001 by Donald J. McCaffrey and Dr. Norman Wong, the company commenced trading on the Toronto Stock Exchange (TSX) under the symbol RVX in 2005. McCaffrey, with over four decades of corporate management and 20 years in drug development, leads the company as President and CEO, leveraging his experience to build international teams and secure major pharmaceutical partnerships. His work extends to co-founding Zenith Epigenetics, a company spun out from Resverlogix in 2013 to focus on oncology.

The company's core business revolves around the discovery and development of small-molecule drugs that regulate gene expression by targeting bromodomain and extraterminal (BET) proteins. As a clinical-stage entity, Resverlogix does not currently generate revenue from product sales; its business model is centered on advancing its lead drug candidate through clinical trials to eventually achieve regulatory approval and commercialization. This strategy involves partnerships with key stakeholders, including pharmaceutical companies, physicians, and health payer groups, to bring its therapies to market. A notable partnership has been established with EVERSANA™ to support the commercialization of its lead product in the United States and Canada.

Resverlogix's lead product is apabetalone, a first-in-class BET inhibitor discovered in 2006. Apabetalone works at the transcriptional level, selectively inhibiting BET proteins to normalize the expression of genes that contribute to chronic diseases. This mechanism allows it to simultaneously influence multiple disease-related biological processes, including inflammation, lipid metabolism, and vascular health. The primary target indication for apabetalone is high-risk cardiovascular disease in patients with type 2 diabetes mellitus and low high-density lipoprotein (HDL) levels, a market segment where existing treatments like statins prevent only a fraction of cardiovascular events. By downregulating pro-inflammatory genes and upregulating ApoA-I (the main protein in HDL), apabetalone has shown potential in clinical trials to reduce Major Adverse Cardiac Events (MACE). The therapy is also being explored for its potential in treating post-COVID-19 conditions and cancer.

Keywords: Resverlogix, apabetalone, epigenetics, BET inhibitors, bromodomain and extraterminal domain, cardiovascular disease, chronic illness, biotechnology, clinical trials, Donald J. McCaffrey, Norman Wong, TSX: RVX, Zenith Epigenetics, lipid metabolism, ApoA-I, MACE, transcriptional regulation